1. Kim MJ, Kim N, Shin D, Rhee SJ, Park CH, Kim H, Yang B, Ahn YM. The epidemiology of antidepressant prescriptions in South Korea from the viewpoint of medical providers: a nationwide register-based study. Korean J Biol Psychiatry 2019;26:39-46.
2. World Health Organization. The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
3. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification system: structure and principles [Internet] Oslo: WHO Collaborating Centre for Drug Statistics Methodology. 2018 [cited 2020 Feb 28]. Available from:
https://www.whocc.no/atc/structure_and_principles
4. Lee JG. Classification of neuropsychiatric drugs and NbN. In: Bahk WM, Kim CH, editor. Textbook of clinical neuropsychopharmacology. 3rd ed. Seoul: Sigma Press; 2019. p. 119-124.
7. Kupfer DJ, Regier DA. Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5. Am J Psychiatry 2011;168:672-674.
8. Whooley O, Horwitz AV. The paradox of professional success: grand ambition, furious resistance, and the derailment of the dsm-5 revision process. In: Paris J, Phillips J, editor. Making the DSM-5: concepts and controversies. New York: Springer; 2013. p. 75-92.
9. Kim YK, Park SC. Classification of psychiatric disorders. Adv Exp Med Biol 2019;1192:17-25.
10. European College of Neuropsychopharmacology. Neuroscience-based Nomenclature, second edition, revised (NbN2R) [Internet] Utrecht: European College of Neuropsychopharmacology. c2017 [cited 2020 Feb 28]. Available from:
https://nbn2r.com
11. Won E, Park SC, Han KM, Sung SH, Lee HY, Paik JW, Jeon HJ, Lee MS, Shim SH, Ko YH, Lee KJ, Han C, Ham BJ, Choi J, Hwang TY, Oh KS, Hahn SW, Park YC, Lee MS; Clinical Research Center for Depression. Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition. J Korean Med Sci 2014;29:468-484.
12. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157((4 Suppl):1-45.
13. Seo JS, Bahk WM, Wang HR, Woo YS, Park YM, Jeong JH, Kim W, Shim SH, Lee JG, Jon DI, Min KJ. Korean medication algorithm for depressive disorders 2017: third revision. Clin Psychopharmacol Neurosci 2018;16:67-87.
14. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391:1357-1366.
15. Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 2016;173:174-183.
16. Maslej MM, Furukawa TA, Cipriani A, Andrews PW, Mulsant BH. Individual differences in response to antidepressants: a meta-analysis of placebo-controlled randomized clinical trials. JAMA Psychiatry 2020;Feb. 19. [Epub].
https://doi.org/10.1001/jamapsychiatry.2019.4815
17. Insel TR. Next-generation treatments for mental disorders. Sci Transl Med 2012;4:155. psc19.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association Publishing; 2013.
19. Ostergaard SD, Jensen SO, Bech P. The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatr Scand 2011;124:495-496.
20. Zimmerman M, Ellison W, Young D, Chelminski I, Dalrymple K. How many different ways do patients meet the diagnostic criteria for major depressive disorder? Compr Psychiatry 2015;56:29-34.
21. Park SC, Kim YK. Depression in DSM-5: changes, controversies and future direction. In: Kim YK, editor. Understanding depression. Volume 2. Clinical manifestations, diagnosis and treatment. New York: Springer Nature; 2018. p. 2-14.
24. Regier DA, Narrow WE, Clarke DE, Kraemer HC, Kuramoto SJ, Kuhl EA, Kupfer DJ. DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. Am J Psychiatry 2013;170:59-70.
25. Park SC, Kim JM, Jun TY, Lee MS, Kim JB, Yim HW, Park YC. How many different symptom combinations fulfil the diagnostic criteria for major depressive disorder? Results from the CRESCEND study Nord J Psychiatry 2017;71:217-222.
26. Rosenman S, Nasti J. Psychiatric diagnoses are not mental processes: Wittgenstein on conceptual confusion. Aust N Z J Psychiatry 2012;46:1046-1052.
27. Wittgenstein L. Philosophical investigations. Translated by Kim YS. Seoul: Dongshuh Press; 2008.
28. Saxe GN. Network psychiatry: computational methods to understand the complexity of psychiatric disorders. J Am Acad Child Adolesc Psychiatry 2017;56:639-641.
29. Russell JD, Neill EL, Carrion VG, Weems CF. The network structure of posttraumatic stress symptoms in children and adolescents exposed to disasters. J Am Acad Child Adolesc Psychiatry 2017;56:669-677.
31. Fried EI, Epskamp S, Nesse RM, Tuerlinckx F, Borsboom D. What are ‘goodʼ depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis J Affect Disord 2016;189:314-320.
32. Kendler KS, Aggen SH, Flint J, Borsboom D, Fried EI. The centrality of DSM and non-DSM depressive symptoms in Han Chinese women with major depression. J Affect Disord 2018;227:739-744.
33. Park SC, Jang EY, Xiang YT, Kanba S, Kato TA, Chong MY, Lin SK, Yang SY, Avasthi A, Grover S, Kallivayalil RA, Udomratn P, Chee KY, Tanra AJ, Tan CH, Sim K, Sartorius N, Park YC, Shinfuku N. Network analysis of the depressive symptom profiles in Asian patients with depressive dis-orders: Findings from the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD). Psychiatry Clin Neurosci 2020;Feb. 12. [Epub].
https://doi.org/10.1111/pcn.12989
35. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008;65:870-880.
36. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
38. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011;168:689-701.
39. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-583.
40. Shiloh R, Stryjer R, Weizman A, Nutt D. Atlas of psychiatric pharmacotherapy. 2nd ed. London: Taylor and Francis; 2006.
41. Stahl SM. Stahlʼs illustrated antidepressants. Cambridge: Cambridge University Press; 2009.
42. Stahl SM. Stahlʼs essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. Cambridge: Cambridge University Press; 2013.